Vital Biopharmaceutical Insights and Analytics

for Experts from Experts

Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.

Learn More

Type 2 Diabetes Inadequately Controlled with Diet and Exercise: When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers?

Eli Lilly’s insulin peglispro is set to become the clinical gold-standard in the treatment of patients with type 2 diabetes inadequately controlled with diet and exercise, when metformin is not a therapeutic option... Learn More

Chronic Myeloid Leukemia: Prescribing Decisions and Payer Landscape in the United States and Europe

Join us live on August 13, 2014... Learn More

View Webinar schedule and archive

Search Reports


See which reports have been searched on the most.



TreatmentTrends: Acute Kidney Injury (US) 2014

In this new report, both surveyed nephrologists and critical care physicians report that there is a high perceived need for new therapies for the treatment of acute kidney injury (AKI).


View sample slides from this report to learn more about our analysis of physicians’ practice patterns, attitudes and perceptions of projected use of various products in development for AKI.

Recent Reports [ view all ]

  • FY2014 NHI Drug Pricing Reform in Japan

    Hurdles for new price premiums appear too high, while overall negative effects from other price revisions are expected... Read More

  • Multiple Sclerosis - 2014

    Last Updated 23 July 2014
    The market for disease-modifying multiple sclerosis (MS) therapies is in the... Read More

  • Unipolar Depression - 2014

    Last Updated 22 July 2014
    Unipolar depression—comprising major depressive disorder (MDD), minor... Read More

Decision Resources Group brands include: